JP6433922B2 - インダゾール誘導体の調製に使用するための中間体およびその調製方法 - Google Patents

インダゾール誘導体の調製に使用するための中間体およびその調製方法 Download PDF

Info

Publication number
JP6433922B2
JP6433922B2 JP2015559311A JP2015559311A JP6433922B2 JP 6433922 B2 JP6433922 B2 JP 6433922B2 JP 2015559311 A JP2015559311 A JP 2015559311A JP 2015559311 A JP2015559311 A JP 2015559311A JP 6433922 B2 JP6433922 B2 JP 6433922B2
Authority
JP
Japan
Prior art keywords
compound
formula
alkali metal
catalyst
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015559311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516670A5 (enExample
JP2016516670A (ja
Inventor
トッド シー. エアリー,
トッド シー. エアリー,
ブルーノ ピー. ハッシュ,
ブルーノ ピー. ハッシュ,
デリック ユルンスト,
デリック ユルンスト,
ステイシー ルネ スペンサー,
ステイシー ルネ スペンサー,
ピーター ジェイ. ステンゲル,
ピーター ジェイ. ステンゲル,
ダニエル ジョン ワトソン,
ダニエル ジョン ワトソン,
Original Assignee
アレイ バイオファーマ、インコーポレイテッド
アレイ バイオファーマ、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレイ バイオファーマ、インコーポレイテッド, アレイ バイオファーマ、インコーポレイテッド filed Critical アレイ バイオファーマ、インコーポレイテッド
Publication of JP2016516670A publication Critical patent/JP2016516670A/ja
Publication of JP2016516670A5 publication Critical patent/JP2016516670A5/ja
Application granted granted Critical
Publication of JP6433922B2 publication Critical patent/JP6433922B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015559311A 2013-02-27 2014-02-27 インダゾール誘導体の調製に使用するための中間体およびその調製方法 Active JP6433922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770031P 2013-02-27 2013-02-27
US61/770,031 2013-02-27
PCT/US2014/019039 WO2014134313A1 (en) 2013-02-27 2014-02-27 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof

Publications (3)

Publication Number Publication Date
JP2016516670A JP2016516670A (ja) 2016-06-09
JP2016516670A5 JP2016516670A5 (enExample) 2017-03-23
JP6433922B2 true JP6433922B2 (ja) 2018-12-05

Family

ID=50288305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559311A Active JP6433922B2 (ja) 2013-02-27 2014-02-27 インダゾール誘導体の調製に使用するための中間体およびその調製方法

Country Status (5)

Country Link
US (1) US9790206B2 (enExample)
EP (1) EP2961744B1 (enExample)
JP (1) JP6433922B2 (enExample)
CN (1) CN105073739B (enExample)
WO (1) WO2014134313A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601593B (zh) 2017-10-05 2022-04-15 弗尔康医疗公司 P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4617299B2 (ja) 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド p38阻害剤及びその使用法
AU2007210073B2 (en) * 2006-01-31 2011-10-06 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
JP2009531445A (ja) * 2006-03-29 2009-09-03 アレイ バイオファーマ、インコーポレイテッド p38インヒビターおよびその使用方法
TWI365185B (en) * 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
CN102510862A (zh) * 2009-07-14 2012-06-20 阿尔巴尼分子研究公司 5-ht3受体调节剂、其制备方法和用途

Also Published As

Publication number Publication date
US9790206B2 (en) 2017-10-17
WO2014134313A1 (en) 2014-09-04
US20160002210A1 (en) 2016-01-07
CN105073739B (zh) 2017-10-24
EP2961744A1 (en) 2016-01-06
EP2961744B1 (en) 2017-06-28
JP2016516670A (ja) 2016-06-09
CN105073739A (zh) 2015-11-18

Similar Documents

Publication Publication Date Title
JP5107267B2 (ja) 置換ビフェニルの製造法
ES2882543T3 (es) Proceso para la preparación de 4-amino-piridazinas
TWI631121B (zh) 製備細胞凋亡誘導劑的方法
US20110003999A1 (en) Process for Preparing Substituted Biphenylanilides
KR102671396B1 (ko) 프로테인 카이네이즈에 대한 선택적 억제제의 합성에 유용한 중간체 및 이의 제조방법
US9051272B2 (en) Process for the preparation of phenyl substituted 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid N-methoxy-[1-methyl-2 phenylethyl] amides
CN103153960B (zh) 制备取代的n-苯基羟胺的方法
JP2019504883A (ja) ピラゾールを調製する接触水素化方法
JP5138386B2 (ja) 置換ビフェニル類の製造方法
JP6433922B2 (ja) インダゾール誘導体の調製に使用するための中間体およびその調製方法
JP5512551B2 (ja) 置換ビフェニルアニリド類を調製する方法
CA2965590A1 (en) Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
JP5096354B2 (ja) カルボキサニリドの製造方法
CN105658627B (zh) 芳香胺的单芳基化
KR101974850B1 (ko) 아세트아미노펜의 신규한 제조방법
JP2021075535A (ja) ピリミジン誘導体およびそれらの中間体を調製する化学的方法
CN108699009A (zh) 制备3-哌嗪-1-基-丙基胺衍生物的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181107

R150 Certificate of patent or registration of utility model

Ref document number: 6433922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250